Grow Opportunity

News Business International Medical
Avicanna and Ease Labs Pharma granted commercialization approval for pharmaceutical preparation in Brazil

January 30, 2024  By Grow Opportunity Staff

(Globe Newswire) Toronto — Avicanna Inc. a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce ANVISA has granted commercialization approval of Ease Labs Pharma pharmaceutical preparation produced in Brazil containing Avicanna’s Aureus branded active pharmaceutical ingredient.

Ease Labs, a GMP-certified pharmaceutical company in Brazil, was granted approval from ANVISA to commercialize a pharmaceutical preparation product containing 2.5 per cent of CBD and up-to 0.2 per cent THC. This is the first product containing THC granted sanitary authorization under the RDC 327 and GMP certified manufacturing standards in Brazil. Ease Labs expects the product to be available in pharmacies with a medical prescription by March 2024.

“This is the first full spectrum product containing THC manufactured in Brazil approved by ANVISA under the RDC 327 regulations, which we believe will provide new treatment options to patients with different diseases. We are confident that the combination of local infrastructure and agreement with Avicanna will allow us to deliver these products into the market at a rapid rate and at accessible pricing for the patients,” explains Gustavo Palhares, Ease Labs CEO and co-founder.

The full spectrum API is supplied by Avicanna’s majority owned subsidiary Santa Marta Golden Hemp SAS, under a multi-year API supply agreement entered in 2021.


“We are appreciative of the confidence and trust Ease Labs placed in us and the work done these past years which resulted in the achievement of this incredible milestone. We are happy to see the new treatment options will be made available to patients with greater accessibility and look forward to the continued relationship,” stated Aras Azadian, Avicanna CEO.

Print this page


Stories continue below